All In Biotech

NDA 022453 · Meitheal

Topotecan Hydrochloride

Topotecan Hydrochloride · Intravenous

Discontinued

Last checked: Nov 20, 2026Latest source record: Jun 24, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Dec 20, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

477

118 Phase 3, 54 recruiting

FAERS reports

833

808 serious, 134 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • TOPOTECAN HYDROCHLORIDE · TOPOTECAN HYDROCHLORIDE EQ 4MG BASE/4ML (EQ 1MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Topotecan" as an intervention, any sponsor and status, largest first.

All 477 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia184
  • pyrexia124
  • off label use100
  • neutropenia81
  • vomiting78
  • anaemia67
  • diarrhoea67
  • neoplasm progression57
  • product use in unapproved indication55
  • pancytopenia54
  • body temperature increased47
  • headache47

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20054
20066
200714
20086
20098
201013
201122
201225
201322
201425
201530
201615
201750
201873
201974
202062
202179
202296
202380
202447
202538
202644

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 785 on PubMed

Sponsor: Meitheal

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.